Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra

被引:95
作者
Kocagoz, T
Hackbarth, CJ
Unsal, I
Rosenberg, EY
Nikaido, H
Chambers, HF
机构
[1] UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94110 USA
[2] UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, BERKELEY, CA 94720 USA
[3] HECETTEPE UNIV, DEPT MICROBIOL, ANKARA, TURKEY
关键词
D O I
10.1128/AAC.40.8.1768
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
To characterize mechanisms of resistance to fluoroquinolones by Mycobacterium tuberculosis, mutants of strain H37Ra were selected in vitro with ofloxacin. Their quinolone resistance-determining regions of gyrA and gyrB were amplified and sequenced to identify mutations in gyrase A or B, Three types of mutants were obtained: (i) one mutant (TKp1) had no mutations in gyrA or gyrB; (ii) mutants that had single missense mutations in gyrA, and (iii) mutants that had two missense mutations resulting in either two altered gyrase A residues or an altered residue in both gyrases A and B, The TKp1 mutant had slightly reduced levels of uptake of [C-14]norfloxacin, which was associated with two- to fourfold increases in the MICs of ofloxacin, ciprofloxacin, and sparfloxacin. Gyrase mutations caused a much greater increase in the MICs of fluoroquinolones, For mutants with single gyrA mutations, the increases in the MICs were 4 to 16-fold, and for mutants with double gyrase mutations, the MICs were increased 32-fold or more compared with those for the parent. A gyrA mutation in TKp1 secondary mutants was associated with 32- to 128-fold increases in the MICs of ofloxacin and ciprofloxacin compared with the MICs for H37Ra and an eight-fold increase in the MIC of sparfloxacin. Sparfloxacin was the most active fluoroquinolone tested, No sparfloxacin-resistant single-step mutants were selected at concentrations of >2.5 mu g/ml, and high-level resistance (i.e., MIC, greater than or equal to 5 mu g/ml) was associated with two gyrase mutations. Mutations in gyrB and possibly altered levels of intracellular accumulation of drug are two additional mechanisms that may be used by M. tuberculosis in the development of fluoroquinolone resistance, Because sparfloxacin is more active in vitro and selection of resistance appears to be less likely to occur, it may have important advantages over ofloxacin or ciprofloxacin for the treatment of tuberculosis.
引用
收藏
页码:1768 / 1774
页数:7
相关论文
共 50 条
[1]   CHARACTERIZATION OF FLUOROQUINOLONE-RESISTANT MUTANT STRAINS OF MYCOBACTERIUM-TUBERCULOSIS SELECTED IN THE LABORATORY AND ISOLATED FROM PATIENTS [J].
ALANGADEN, GJ ;
MANAVATHU, EK ;
VAKULENKO, SB ;
ZVONOK, NM ;
LERNER, SA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (08) :1700-1703
[2]  
ARIZA RR, 1994, J BACTERIOL, V152, P636
[3]   IMPERMEABILITY TO QUINOLONES IN GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA [J].
BRYAN, LE ;
BEDARD, J .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (04) :232-239
[4]  
Cambau E, 1993, Drugs, V45 Suppl 3, P15
[5]  
CAMBAU E, 1994, FEMS MICROBIOL LETT, V116, P49
[6]   CAN PENICILLINS AND OTHER BETA-LACTAM ANTIBIOTICS BE USED TO TREAT TUBERCULOSIS [J].
CHAMBERS, HF ;
MOREAU, D ;
YAJKO, D ;
MIICK, C ;
WAGNER, C ;
HACKBARTH, C ;
KOCAGOZ, S ;
ROSENBERG, E ;
HADLEY, WK ;
NIKAIDO, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (12) :2620-2624
[7]   MINIMAL INHIBITORY CONCENTRATIONS OF RIFABUTIN, CIPROFLOXACIN, AND OFLOXACIN AGAINST MYCOBACTERIUM-TUBERCULOSIS ISOLATED BEFORE TREATMENT OF PATIENTS IN TAIWAN [J].
CHEN, CH ;
SHIH, JF ;
LINDHOLMLEVY, PJ ;
HEIFETS, LB .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1989, 140 (04) :987-989
[8]   ENDOGENOUS ACTIVE EFFLUX OF NORFLOXACIN IN SUSCEPTIBLE ESCHERICHIA-COLI [J].
COHEN, SP ;
HOOPER, DC ;
WOLFSON, JS ;
SOUZA, KS ;
MCMURRY, LM ;
LEVY, SB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (08) :1187-1191
[9]   CIPROFLOXACIN AND SPARFLOXACIN PENETRATION INTO HUMAN BRAIN-TISSUE AND THEIR ACTIVITY AS ANTAGONISTS OF GABA(A) RECEPTOR OF RAT VAGUS NERVE [J].
DAVEY, PG ;
CHARTER, M ;
KELLY, S ;
VARMA, TRK ;
JACOBSON, I ;
FREEMAN, A ;
PRECIOUS, E ;
LAMBERT, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (06) :1356-1362
[10]   ROLE OF THE OUTER-MEMBRANE FOR QUINOLONE RESISTANCE IN ENTEROBACTERIA [J].
DECHENE, M ;
LEYING, H ;
CULLMANN, W .
CHEMOTHERAPY, 1990, 36 (01) :13-23